Alzheimer Disease in Latinos: A Growing Public Health Crisis
The prevalence of Alzheimer disease in Latinos is rising at a rate that researchers and public health experts describe as one of the most urgent and underaddressed challenges in American healthcare. A report by the Edward R. Roybal Institute on Aging at the University of Southern California and the Latinos Against Alzheimer network found that if no cure is discovered, the number of Latinos living with Alzheimer disease will increase more than eight times, reaching 3.5 million by 2060.
Across the broader U.S. population, the Alzheimer’s Association projects that total cases could nearly triple by 2050, reaching approximately 13.8 million. But the trajectory for Latino communities is steeper and faster, driven by a combination of demographic growth, elevated chronic disease burden, and persistent gaps in awareness and diagnosis.
Why Alzheimer Disease in Latinos Carries Higher Risk
Latinos as a group are 50 percent more likely than non-Hispanic whites to develop Alzheimer disease, according to the Roybal Institute report. Several factors contribute to this elevated risk.
The Latino senior population is growing more than three times faster than that of non-Hispanic whites, meaning a larger share of the community will be in the age range where Alzheimer disease risk is highest. At the same time, Latinos have disproportionately high rates of chronic conditions known to increase Alzheimer disease risk, including diabetes, obesity, high blood pressure, high cholesterol, and cardiovascular disease. Dr. William Vega, executive director of the Roybal Institute, estimated that approximately one third of the Latino population in the United States is at elevated risk due to these overlapping health factors.
Lifestyle induced conditions that damage blood vessels and impair circulation to the brain are strongly associated with cognitive decline. While age, family history, and genetics remain the primary non modifiable risk factors, addressing conditions like diabetes and hypertension through lifestyle change and medical management may help reduce risk at the population level.
The Diagnosis Gap and Cultural Barriers
One of the most troubling dimensions of Alzheimer disease in Latinos is the pattern of late or absent diagnosis. Despite being significantly more likely to develop the disease, Latinos are frequently diagnosed later than non-Hispanic whites, or not diagnosed at all. Researchers point to a combination of limited awareness and cultural attitudes that discourage acknowledgment of cognitive symptoms.
Francisca Reynoso, who coordinates a caregiver support group for Alzheimer’s Greater Los Angeles, noted that within Latino culture there is often a reluctance to recognize Alzheimer disease as a medical condition rather than a normal part of aging. Family caregivers frequently minimize or deny symptoms, and community members may lack the basic information needed to identify early warning signs. Dr. Vega emphasized that one practical step toward better outcomes is education around the fact that Alzheimer disease is not an inevitable consequence of growing old.
Underrepresentation in Clinical Trials
A particularly critical issue is the severe underrepresentation of Latinos in Alzheimer disease clinical research. Although Latinos represent approximately 17 percent of the U.S. population, they account for only 1 percent of participants in clinical trials focused on Alzheimer disease treatment and prevention. This gap has direct consequences for the quality of evidence available to guide care in this population.
Medications and interventions tested predominantly in non-Hispanic white populations may not produce the same effects across different ethnic groups. Without diverse trial enrollment, it is impossible to know whether treatments are equally safe and effective for Latino patients. Closing this gap is not only a matter of scientific rigor. It is a matter of health equity. FOMAT is committed to inclusive clinical research and actively works to ensure that underrepresented communities have access to and participation in trials across therapeutic areas. Learn more about our commitment to diversity in clinical trials.
The Economic and Caregiver Burden
The cumulative economic impact of Alzheimer disease in Latinos is projected to reach $2.35 trillion by 2060, according to the Roybal report. This figure encompasses direct medical and long term care costs, as well as lost income among family members who provide unpaid care at home.
The caregiving burden falls heavily on Latino families. Latinos with Alzheimer disease are more likely than non-Latinos to be cared for by family members rather than in formal care settings. A study by the National Alliance for Caregiving found that 63 percent of Latino caregivers are in overload situations, providing more than 50 hours of care per week, compared to 51 percent of non-Latino caregivers. This level of unpaid caregiving has significant consequences for the health, employment, and financial stability of the caregivers themselves.
For a thorough overview of risk factors, symptoms, and available resources, the Mayo Clinic provides a comprehensive and accessible guide.
Clinical Research and the Path Forward
Addressing Alzheimer disease in Latinos will require more than awareness campaigns. It demands increased investment in clinical research that includes Latino participants, culturally informed outreach, and the development of treatments tested across diverse populations.
FOMAT supports clinical research across neurology and multiple therapeutic areas through a national network of investigator sites. To learn about active studies, visit our patient active studies page. For more health and research insights, explore the FOMAT blogs and updates.